Pharmacogenetics studies the genes that regulate the activity, metabolism and transport of drugs, identifying the genetic polymorphisms involved in each process.
The most frequent cause of therapeutic failure and adverse reactions is found in the variability of each patient’s response to drugs.
The individual pharmacogenetic profile allows the use of the most indicated drug in each case and the correct dose. In this way, the treatment is safer and more effective, the appearance of adverse effects is reduced.

The gene that codes for complement factor H (CFH) has been postulated as a candidate gene when participating in inflammatory processes, being the main regulator of the alternative complement system.

It has been shown that the variant Tyr402His (Y402H), resulting from the substitution c.1204T> C, predicts the response to treatment with antiangiogenic substances, thus being able to identify those people who will respond well, people in whom it will be indicated the treatment with a standard dose of the drug.

One in four patients with macular degeneration has a Y402H genotype in homozygosis associated with a low response to treatment with antiangiogenic agents; in these cases it is indicated to schedule longer treatments.

Patients with one or no copy of the variant respond in a standard way to treatment, so that the doses and treatment periods are initially established.

The test can be done from peripheral blood or buccal mucosa cells.

The result is issued in 25 days.